CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway
Sartelet H et al. – CD133high cells expressed significantly higher levels of pAKT than CD133low cells. LY294002 treatment abolished the preferential survival of CD133high cells. CD133 is associated with in–vitro resistance to chemotherapy involving activation of the AKT pathway.